跳至主要内容
临床试验/NCT04859322
NCT04859322已完成不适用

The Effect of Lifestyle-induced Hepatic Steatosis on Glucagon-stimulated Amino Acid Turnover

Malte Palm Suppli, MD1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2021年2月8日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
20
试验地点
1
主要终点
Nadir of the total amino acid concentration during a two-hour high physiological glucagon infusion during a pancreatic clamp with somatostatin

研究概览

简要总结

Many patients with type 2 diabetes exhibit elevated plasma concentrations of the glucose-mobilising pancreatic hormone glucagon; i.e. hyperglucagonaemia. This contributes to the hyperglycaemic state of the patients and is considered an important component in the pathophysiology of type 2 diabetes; but the mechanisms underlying this phenomenon remain unclear. The liver constitutes the main target organ of glucagon, and studies have shown that hyperglucagonaemia goes hand in hand with hyperaminoacidaemia and that both are associated with non-alcoholic fatty liver disease (NAFLD), independently of the presence of type 2 diabetes. In line with this, several recent studies support the existence of a feedback-cycle between the liver and the pancreatic alpha cells, governed by circulating glucagon and amino acids. The investigators hypothesise that the presence of hepatic steatosis results in hepatic glucagon resistance at the level of amino acid turnover, i.e. impaired glucagon-induced suppression of circulating amino acid concentrations. If this hypothesis proves correct, it would establish build-up of fat in the liver as a core mechanism underlying hyperglucagonaemia and, since the hyperglucagonemia is at least partly responsible for the fasting hyperglycaemia, as an important contributor to the hyperglycaemia of type 2 diabetes.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Basic Science
盲法
None

入排标准

年龄范围
20 Years 至 65 Years(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Normal fasting plasma glucose and glycated haemoglobin (HbA1c) <42 mmol/mol
  • Body mass index (BMI) between 18.5 and 25 kg/m2
  • Haemoglobin >8.3 mmol/l
  • Habitual diet in accordance with the Nordic Nutrition Recommendations
  • Age between 20 and 65 years
  • Oral and written informed consent

排除标准

  • First-degree relatives with diabetes
  • Fasting plasma triacylglycerol indicating dyslipidemia (≥2 mmol/l)
  • Nephropathy (estimated glomerular filtration rate (eGFR) <60 ml/min and/or microalbuminuria with an albumin to creatinine ratio of 30-300 μg/mg)
  • Known liver disease and/or alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) >2 × normal values
  • Signs of liver fibrosis and/or steatosis evaluated by FibroScan (CAP value >2380 dB/m and/or kPa >65.0) and/or FIB-4 score (>1.45)
  • >5% steatosis evaluated by MRI carried out before experimental Day A (see Methods)
  • Use of medication
  • Use of dietary protein supplementation or any other dietary supplements that cannot be paused during participation
  • Excessive training habits, defined as >2 weekly strength and/or aerobic training sessions
  • Pregnancy and/or breastfeeding
  • Implanted metal objects incompatible with magnetic resonance imaging (MRI)
  • Any condition that the investigator feels would interfere with trial completion

研究组 & 干预措施

Healthy Participants

Experimental

20 healthy participants included in the arm for 3 experimental days each. On each experimental day infusions of stable isotope glucose (0,6 micromol/kg/min), glucagon (1 hour low; 0,6 ng/kg/min, 2 hours high; 4,0 ng/kg/min), somatostatin (450 micrograms/hour) and insulin (0,1 mU/kg/min) will be administered. Between the first two experimental days the participants will follow a sedentary lifestyle combined with a high-calorie diet intervention

干预措施: Glucagon (Drug)

结局指标

主要结局

Nadir of the total amino acid concentration during a two-hour high physiological glucagon infusion during a pancreatic clamp with somatostatin

时间窗: depending on the nadir between time 60 minutes and time 180 minutes

micromol/liter

次要结局

  • the percentage change in amino acid concentration during the last hour of the 'supraphysiological' glucagon infusion as assessed by baseline subtracted AUC(between time 60 minutes and time 180 minutes)
  • average slope of the curve describing the change in the total amino acid concentration during 'supraphysiological' glucagon infusion(between time 60 minutes and time 180 minutes)
  • the incremental area under the curve (iAUC) for total amino acid concentrations during 'supraphysiological' glucagon infusion(between time 60 minutes and time 180 minutes)

研究者

发起方
Malte Palm Suppli, MD
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Malte Palm Suppli, MD

MD

University Hospital, Gentofte, Copenhagen

研究点 (1)

Loading locations...

相似试验